Pelage Pharmaceuticals Announces $16.75M Series A

Feb 27, 2024•almost 2 years ago

Amount Raised

$16.8 Million

Round Type

series a

Los AngelesBiotechnologyHealthcare

Investors

Yk Bio VenturesVisionary VenturesMain Street AdvisorsGv

Description

Pelage Pharmaceuticals raised $16.75M in Series A funding led by GV with participation from Main Street Advisors, Visionary Ventures, and YK BioVentures. The company plans to use the funds to advance a first-in-class treatment for androgenetic alopecia, pattern baldness, and other types of alopecia, including chemotherapy-induced hair loss.

Company Information

Company

Pelage Pharmaceuticals

Location

Los Angeles, California, United States

About

Pelage Pharmaceuticals is a clinical-stage regenerative medicine company developing first-in-class treatments for hair loss. With a focus on stem cell biology and metabolism, Pelage is advancing a new class of treatments designed to reactivate dormant hair follicle stem cells and restore the body’s ability to naturally grow hair. Its lead program, PP405, is currently in Phase 2a clinical trials. Through its rigorous scientific foundation, Pelage is pioneering first-in-class hair growth solutions for people of all hair types experiencing hair loss.

Related People

3 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends